Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry

Abstract

We sought to determine the efficacy of a new, inexpensive, single-tube 8-color multiparameter flow cytometry (MFC) method (SRL-Flow), which is based on the EuroFlow next-generation flow (NGF) (tube 2 only), to assess minimal residual disease (MRD)-negative status. MRD-negative status is considered a treatment milestone in multiple myeloma (MM). We used 45 bone marrow samples from patients with MM, including 11 cases treated with anti-CD38 monoclonal antibody. The SRL-Flow sample preparation protocol was identical to that of EuroFlow-NGF. The antibody panel for SRL-Flow was as follows: CD138V450/CD27V500/CD38ME (multiepitope)FITC/CD56PE/CD45PerCP-Cy5.5/CD19PE-Cy7/cytoplasmic (Cy) immunoglobulin (Ig) κAPC/CyIgλAPC-H7. To identify abnormal plasma cells (aPCs) of patients with MM who received anti-CD38 monoclonal antibody, we used a panel of anti-CD45 and anti-CD138 antibodies (Abs) rather than a panel of anti-CD45 and anti-CD38 Abs. We comparatively analyzed the total nucleated cell numbers, total PC levels, and MRD levels between the SRL-Flow and EuroFlow-NGF. High correlations (r > 0.9) in total PC and MRD levels were noted among SRL-Flow, original EuroFlow-NGF (2 tubes), and EuroFlow-NGF (tube 2 only), suggesting that SRL-Flow is an inexpensive (< $200 USD/sample as of January of 2019) alternative to EuroFlow-NGF (< $350 USD/sample) for assessing MRD in MM.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

Change history

  • 21 March 2019

    The authors would like to correct the error in the publication of the original article. The corrected detail is given below for your reading.

References

  1. 1.

    Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017;281:365–82.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Roshal M, Flores-Montero JA, Gao Q, Koeber M, Wardrope J, Durie BGM, et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv. 2017;1:728–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Narita K, Kobayashi H, Abe Y, Kitadate H, Takeuchi M, Matsue K. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma. Int J Hematol. 2018;108:371–4.

    Article  PubMed  Google Scholar 

  4. 4.

    Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-48.

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90:31–9.

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328-e46.

    Article  Google Scholar 

  8. 8.

    Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Flores-Montero J, de Tute R, Paiva B, Perez JJ, Bottcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90:61–72.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, et al. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica. 2017;102:e368-e70.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge Dr Juan Flores-Montero, Dr Luzalba Sanoja-Flores and Prof Alberto Orfao of Universidad de Salamanca for the EuroFlow-NGF assessments.

Author information

Affiliations

Authors

Contributions

HT conceived and designed the study; HT, TY, MF, KK, MH, TY, RM, MU, SN and KM acquired the data; HT, TY, KK, MH, and KM assembled, analyzed and interpreted the data; HT wrote the manuscript; and all authors reviewed the manuscript.

Corresponding author

Correspondence to Hiroyuki Takamatsu.

Ethics declarations

Conflict of interest

H.T. and K.M. received research funding from SRL, Inc. K.K. and M.H. are employees of SRL, Inc. The remaining authors declare no competing financial interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 9724 KB)

About this article

Verify currency and authenticity via CrossMark

Cite this article

Takamatsu, H., Yoroidaka, T., Fujisawa, M. et al. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol 109, 377–381 (2019). https://doi.org/10.1007/s12185-019-02615-z

Download citation

Keywords

  • Myeloma
  • Minimal residual disease
  • Multiparameter flow cytometry
  • EuroFlow